Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to assess the safety of Mylotarg therapy in routine practice.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Gemtuzumab

Criteria

Inclusion Criteria:

• Treated by Mylotarg

• Provide ICF